26 completed, 10 terminated, 3 unknown, 2 recruiting. 44 Phase 2, 5 Phase 3, 3 Phase 1.
Follow Hypopituitarism: new trials by email Literature Review of Hypopituitarism trials Research Report on Hypopituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency Inpegsomatropin Injection, Placebo for Inpegsomatropin Injection - Adult Growth Hormone Deficiency | Phase 2 | Recruiting | Xiamen Amoytop Biotech Co., Ltd. | 36 | 2026-06-10 | 2026-07-22 |
| A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) GS3-007a dry suspension, Insulin - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Changchun GeneScience Pharmaceutical Co., Ltd. | 120 | 2025-12-19 | 2026-05-22 |
| Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency GB08, Norditropin NordiFlex - Growth Hormone Deficiency in Children, Growth Hormone Deficiency (GHD) | Phase 2 / Phase 3 | Not yet recruiting | Shenzhen Kexing Pharmaceutical Co., Ltd. | 268 | 2025-08-31 | 2025-08-22 |
| Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT) Recombinant human growth hormone - Gulf War Syndrome, Adult Growth Hormone Deficiency | Phase 2 | Recruiting | Baylor College of Medicine | 20 | 2024-03-11 | 2026-05-08 |
| A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) LUM-201 - Growth Hormone Deficiency | Phase 2 | Enrolling by invitation | Lumos Pharma | 60 | 2023-08-01 | 2024-02-15 |
| Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) LUM-201 - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 15 | 2022-02-18 | 2026-05-15 |
| PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) LUM-201 - Growth Hormone Deficiency | Phase 2 | Active not recruiting | Lumos Pharma | 24 | 2021-07-14 | 2023-10-04 |
| Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) LUM-201, rhGH Norditropin® pen (34 µg/kg) - Growth Hormone Deficiency | Phase 2 | Completed | Lumos Pharma | 104 | 2020-12-31 | 2026-06-17 |
| Growth Hormone Replacement Therapy for Retried Professional Football Players Growth Hormone, Placebo - TBI (Traumatic Brain Injury), Concussion, Brain | Phase 2 | Unknown | Center for Neurological Studies | 42 | 2019-10-08 | 2023-02-08 |
| Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children Y-shape pegylated somatropin, Norditropin®, Norditropin - Growth Hormone Deficiency | Phase 2 / Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 434 | 2018-12-26 | 2024-01-24 |
| A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD Somatropin Injection - Adult Growth Hormone Deficiency | Phase 2 | Unknown | Changchun GeneScience Pharmaceutical Co., Ltd. | 180 | 2017-04-01 | 2017-04-07 |
| Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD) somavaratan - Adult Growth Hormone Deficiency (AGHD) | Phase 2 | Terminated | Versartis Inc. | 36 | 2016-02-11 | 2023-04-13 |
| Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency GX-H9, Genotropin - Growth Hormone Deficiency | Phase 2 | Completed | Genexine, Inc. | 56 | 2016-01-18 | 2020-04-20 |
| Versartis International Trial in Adults With Long-Acting Growth Hormone somavaratan - Adult Growth Hormone Deficiency | Phase 2 | Completed | Versartis Inc. | 36 | 2015-07-01 | 2022-07-26 |
| A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9 GX-H9, Genotropin - Adult Growth Hormone Deficiency | Phase 2 | Completed | Genexine, Inc. | 45 | 2015-01-01 | 2017-09-07 |
| A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children TV-1106, somatropin - Growth Hormone-Deficiency | Phase 2 | Terminated | Teva Pharmaceutical Industries, Ltd. | 65 | 2014-04-30 | 2021-11-09 |
| Versartis Long-Term Safety Study of Somavaratan somavaratan - Pediatric Growth Hormone Deficiency | Phase 2 / Phase 3 | Terminated | Versartis Inc. | 385 | 2014-03-03 | 2018-03-09 |
| Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children MOD-4023 - Growth Hormone Deficiency (GHD) | Phase 2 | Completed | OPKO Health, Inc. | 48 | 2014-02-01 | 2025-04-09 |
| Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) ACP-001, Human Growth Hormone - Growth Hormone Deficiency (GHD) | Phase 2 | Completed | Ascendis Pharma A/S | 53 | 2013-07-01 | 2026-07-08 |
| Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency TV-1106, Recombinant human growth hormone - Growth Hormone Deficiency | Phase 2 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 52 | 2013-03-31 | 2021-12-10 |
Showing 20 of 44. Sign in to see all of them.
Dwarfism, Pituitary (44) · Dwarfism (4) · Brain Concussion (1) · Brain Injuries, Traumatic (1) · Cognition Disorders (1) · Fibromyalgia (1) · Growth Disorders (1) · Heart Failure (1) · Hypogonadism (1) · Myocardial Ischemia (1) · Obesity (1) · Obesity, Abdominal (1) · Overweight (1) · Persian Gulf Syndrome (1)
Bone Diseases (44) · Bone Diseases, Developmental (44) · Bone Diseases, Endocrine (44) · Brain Diseases (44) · Central Nervous System Diseases (44) · Endocrine System Diseases (44) · Hypothalamic Diseases (44) · Musculoskeletal Diseases (44) · Nervous System Diseases (44) · Pituitary Diseases (44) · Dwarfism (40) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Pathological Conditions, Signs and Symptoms (3)
Human Growth Hormone (14) · Growth Hormone (10) · Growth Hormone-Releasing Hormone (3) · GX-H9 (2) · MOD-4023 (2) · albusomatropin (2) · Amitriptyline (1) · Anastrozole (1) · Control Groups (1) · Fluoxetine (1) · Injections (1) · Insulin (1) · NNC126-0083 (1) · Testosterone (1) · Tramadol (1)
Lumos Pharma (4) · Versartis Inc. (4) · Changchun GeneScience Pharmaceutical Co., Ltd. (3) · Altus Pharmaceuticals (2) · Ascendis Pharma A/S (2) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Federico II University (2) · Genexine, Inc. (2) · OPKO Health, Inc. (2) · Pfizer (2) · University of Pennsylvania (2) · Xiamen Amoytop Biotech Co., Ltd. (2) · Aarhus University Hospital (1) · Ambrx, Inc. (1) · Baylor College of Medicine (1)
United States (19) · Hungary (7) · Germany (6) · China (5) · Israel (5) · Poland (5) · Ukraine (5) · Czechia (4) · Denmark (4) · Greece (4) · Australia (3) · Belarus (3) · France (3) · Italy (3) · Russia (3)
Dariush Elahi, PhD (2) · Will Charlton, MD (2) · Albert Nadal, MD (1) · Antonio Cittadini, MD (1) · Cecilia Lansang, MD (1) · Daniela Rogoff, MD, PhD (1) · Eun Jig Lee, MD, PhD (1) · Ference Peter, MD (1) · Guillem Cuatrecasas, MD (1) · Hui Pan, Doctor (1) · Jack A Yanovski, M.D. (1) · Junfen Fu (1)
PMID 18053120, PMID 19654233, PMID 20961566, PMID 21177789, PMID 23015655, PMID 24178787, PMID 24291224, PMID 24423356, PMID 28201598, PMID 28566441, PMID 36034448
2008 (1), P01AG000599 (1), R01AR050618 (1), R01HL085268 (1)